On March 18, 2022, the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Jane Pritchett Henderson, the Company's principal financial officer, to serve as the Company's Chief Business Officer. Ms. Henderson will also continue to serve as the Company's Chief Financial Officer. In connection with Ms. Henderson's appointment as Chief Business Officer, the Board approved an increase in Ms. Henderson's annual base salary to $510,000.